The US Food and Drug Administration is questioning whether Mesoblast Limited’s pivotal Phase III single-arm study of Ryoncil (remestemcel-L) is sufficient to grant approval of the cellular therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients.
While the study met its primary endpoint, the FDA said it does not appear to be adequate and well controlled...





